Core Viewpoint - The nomination of Mr. Shang Jiangan as an independent director candidate for the third board of Shanghai Kaisa Biotechnology Co., Ltd. has been made, with the nominee meeting all necessary qualifications and independence requirements [1][5]. Summary by Sections Nomination and Qualifications - The nominee has a solid understanding of the operations of listed companies and is familiar with relevant laws and regulations, possessing over five years of necessary work experience in law, economics, accounting, finance, or management [1]. - The nominee has completed training and obtained relevant certification recognized by the stock exchange [1]. Independence Criteria - The nominee does not fall under any of the disqualifying conditions, such as holding significant shares in the company or being related to major shareholders [2]. - The nominee has not been involved in any significant business dealings with the company or its controlling shareholders [2]. Record of Conduct - The nominee has no adverse records, including administrative or criminal penalties from the China Securities Regulatory Commission in the last 36 months [3][4]. - The nominee has not been publicly reprimanded by the stock exchange or faced significant credit issues [4]. Additional Compliance - The nominee has passed the qualification review by the nomination committee of the third board of Shanghai Kaisa Biotechnology Co., Ltd. and has no conflicts of interest that could affect independent performance [4].

Board Restructuring - The company is preparing for the election of its third board of directors, which will consist of 9 members: 6 non-independent directors (including 1 employee representative) and 3 independent directors [1][2] - The term for the new board will be three years, starting from the date of approval by the shareholders' meeting [2] Nomination of Candidates - The board has nominated candidates for the third board, including Liu Xiucai, Deng Weidong, Lu Yiyang, Zang Huiqing, and Yang Chen as non-independent directors, and Wu Xiangyang, Shang Jiangang, and Lian Lishuang as independent directors [1][2] - Wu Xiangyang and Lian Lishuang are accounting professionals, and both Wu and Shang have obtained independent director qualification certificates [1] Shareholder Meeting - A temporary shareholders' meeting will be held to review the board restructuring, with cumulative voting to be used for the election of both non-independent and independent directors [2] - The current board will continue to operate until the new board is approved at the shareholders' meeting [2] Acknowledgment of Current Board - The company expresses gratitude to the current board members for their diligent efforts in promoting the company's operations and development during their tenure [2]

Core Viewpoint - The nomination of Ms. Wu Xiangyang as an independent director candidate for the third board of Shanghai Kaisa Biotechnology Co., Ltd. has been made, with the nominator confirming her qualifications and independence [1][5]. Summary by Sections Nomination and Qualifications - The nominator has fully understood the nominee's professional background, education, titles, work experience, and any significant dishonesty records [1]. - The nominee possesses basic knowledge of listed company operations and has over five years of relevant work experience in law, economics, accounting, finance, or management [1]. Compliance with Regulations - The nominee meets the requirements set forth by the Company Law of the People's Republic of China and the relevant regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [1]. - The nominee has undergone training and obtained certification recognized by the stock exchange [1]. Independence Criteria - The nominee does not fall under any categories that would compromise her independence, such as holding significant shares or having close relationships with major shareholders [2]. - The nominee has no adverse records, including administrative or criminal penalties from the China Securities Regulatory Commission in the last 36 months [3][4]. Additional Qualifications - The nominee has not been dismissed from previous independent director roles due to attendance issues and has not served as an independent director in more than three domestic listed companies [4]. - The nominee possesses substantial accounting knowledge and experience, holding qualifications such as a certified public accountant or a senior title in accounting, auditing, or financial management [4]. Verification and Assurance - The nominator has verified the nominee's qualifications according to the self-regulatory guidelines of the Shanghai Stock Exchange and guarantees the truthfulness and completeness of the statements made [5].

上海凯赛生物技术股份有限公司董事、高级管理人员及核心 技术人员所持本公司股份及其变动管理制度 （2025 年 8 月修订） 第一章 总则 第一条 为规范上海凯赛生物技术股份有限公司（以下简称"公司"）对董事、 高级管理人员及核心技术人员所持本公司股份及其变动的管理，根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、 《上市公司股东减持股份管理暂行办法》 《上市公司董事和高级管 理人员所持本公司股份及其变动管理规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》《上海证券交易所上市公司自律监管指引第 8 号——股份变动管理》 《上海证券交易所上市公司自律监管指引第 15 号——股东 及董事、高级管理人员减持股份》等规范性文件及《上海凯赛生物技术股份有限 公司章程》 （以下简称"《公司章程》"）的有关规定，结合公司实际情况，特制定 本制度。 第二条 本制度适用于公司董事、高级管理人员及核心技术人员所持本公司 股份及其变动的管理。 第三条 公司董事、高级管理人员及核心技术人员所持本公司股份，是指登 记在其名下和利用他人账户持有的所有 ...

Core Points - The company, Cathay Biotech Inc., aims to become a leader in the bio-manufacturing industry by utilizing synthetic biology and biochemical methods [5][3] - The company was established as a joint-stock company through the overall change of Shanghai Cathay Biotech Research Center Co., Ltd. and is registered in the Shanghai Market Supervision Administration [3][4] - The company was approved for its initial public offering (IPO) on July 10, 2020, and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 12, 2020, issuing 41.668198 million shares [3][4] Company Structure - The registered capital of the company is RMB 721,289,794 [4] - The company is a permanent joint-stock company, and its legal representative is the chairman elected by the board of directors [4][5] - The company has a total of 721,289,794 shares, all of which are ordinary shares denominated in RMB [10] Share Issuance and Management - The company issues shares based on principles of openness, fairness, and justice, ensuring equal rights for each share of the same category [6][10] - The company prohibits providing financial assistance to individuals purchasing its shares, except for employee stock ownership plans [10][11] - The company can increase its capital through various methods, including issuing shares to unspecified objects or existing shareholders [22] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and supervision of company operations, as well as the right to request meetings and access company documents [33][34] - Shareholders must comply with laws and the company's articles of association, and they are liable for their subscribed shares [39] - The company has provisions for shareholders to propose agenda items for meetings and requires proper notification for meetings [57][60] Governance and Decision-Making - The company’s board of directors is responsible for convening shareholder meetings and making decisions on significant matters such as capital increases, mergers, and financial assistance [45][46] - The company must disclose significant transactions and financial assistance to shareholders and the public [47][48] - The company has established procedures for the convening and conducting of shareholder meetings, ensuring transparency and compliance with legal requirements [63][64]

证券日报网讯8月1日晚间，凯赛生物发布公告称，公司将于2025年8月18日召开2025年第二次临时股东 大会。本次股东大会将审议《关于取消公司监事会并修改公司章程的议案》等多项议案。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/10/22 司 | | ， | 由 | 公 | 原 | 控 | 股 | 股 | 东 | Cathay | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Industrial Biotech Ltd.提议 | | | | | | | | | | | | 回购方案实施期限 | 2024 年 月 日~2025 月 | 10 | 21 | | | 年 | 10 | 20 | 日 | | | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | | | ...

第一章 总 则 上海凯赛生物技术股份有限公司董事会议事规则 （2025 年 8 月修订） 第一条 为了进一步规范上海凯赛生物技术股份有限公司（以下简称"本公 司"）董事会的议事方式和决策程序，促使本公司董事和董事会有效地履行其职 责，提高董事会规范运作和科学决策水平，根据《中华人民共和国公司法》（以 下简称"《公司法》"）以及《上海凯赛生物技术股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，制订本规则。 第二条 董事会是公司经营决策的常设机构，对股东会负责。董事会在第一 条规定的法律、法规、规范性文件、《公司章程》及本规则的规定的职权范围内 行使职权。 第二章 董事会的组成及职责 第三条 董事会由 5 至 9 名董事组成，设董事长 1 人,设副董事长 1 至 2 名， 职工代表董事 1 人。其中独立董事人数不少于董事会人数的三分之一。 第四条 董事由股东会选举或更换，任期 3 年。董事任期届满，可连选连任， 并可在任期届满前由股东会解除其职务。 第五条 董事任期从股东会决议通过之日起计算，至本届董事会任期届满时 为止。董事任期届满未及时改选，在改选出的董事就任前，原董事仍应当依照法 律、行政法规、 ...

上海凯赛生物技术股份有限公司 章 程 2025 年 8 月 | | | 上海凯赛生物技术股份有限公司章程 第一章 总则 第一条 为维护上海凯赛生物技术股份有限公司（以下简称"公司"或"本 公司"）、股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定由上海凯赛生物技术研发中 心有限公司整体变更设立的股份有限公司。公司在上海市市场监督管理局注册登 记，取得统一社会信用代码为 913100007030116706 的《营业执照》。 第三条 公司于 2020 年 6 月 5 日经上海证券交易所审核同意、于 2020 年 7 月 10 日经中国证券监督管理委员会（以下简称"中国证监会"）注册，首次向社 会公众发行人民币普通股 4,166.8198 万股，于 2020 年 8 月 12 日在上海证券交 易所科创板上市。 第八条 董事会选举产生的董事长为公司的法定代表人。董事长辞任的，视 为同时辞去法定代表人，公司将在其辞任之日起 30 日内 ...

上海凯赛生物技术股份有限公司 董事、高级管理人员薪酬管理制度 （2025年8月） 为进一步完善公司董事、高级管理人员的薪酬管理，建立科学 有效的激励与约束机制，调动董事、高级管理人员的积极性和创造性，提 高企业经营效益和管理水平，确保公司发展战略目标的实现，根据国家法律、 法规的规定及《上海凯赛生物科技股份有限公司章程》(以下简称"《公司 章程》")，结合公司实际情况，制定本制度。 本制度所称董事包括公司非独立董事、独立董事以及职工代表 董事。 本制度所称高级管理人员是指公司总裁、副总裁、财务总监、董事会秘 书以及董事会认定的其他高级管理人员。 （四）与责、权、利相匹配的原则。 公司董事会薪酬与考核委员会是对公司董事和高级管理人员进 行考核以及初步确定薪酬方案的管理机构。 公司董事的薪酬方案须报经董事会同意后，提交股东会审议； 高级管理人员的年度薪酬方案须提交董事会审议。 3 公司人力资源部门、财务部门配合董事会薪酬与考核委员会进 行公司董事和高级管理人员薪酬方案的具体实施。 公司董事和高级管理人员的薪酬以公司经营与综合管理情况为基 础，根据经营计划完成情况、分管工作职责及工作目标完成情况、个人履职 及发展情 ...